Yes, and the rough estimate is confirmed, but shortened somewhat, by the just released annual report, under the sub heading ‘Strategic Overview and Likely Developments’ (see page 20), where it states that one of the company’s focuses over the next 12 months will be “near completion” of the SynPath trial.
It’s more important to have a well conducted trial completed later than hoped for than one that is flawed and completed earlier.
Yes, and the rough estimate is confirmed, but shortened...
-
- There are more pages in this discussion • 1,942 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35541 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 2681 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |